View New Articles By
In developing a treatment plan for a patient, doctors rely on genetic tests on biopsied tumors in bulk rather than individual cells, which fails to capture the full extent of cellular diversity within tumors. A more complete picture of what is happening in a lung cancer tumor could yield clues for effective therapies that may benefit patients.
Seven Damon Runyon scientists are recipients of the National Institutes of Health's High-Risk, High-Reward Research awards that will fund highly innovative and unusually impactful biomedical research proposed by extraordinarily creative scientists.
Lung cancer is often missed in its earlier stages and, as a result, is the leading cause of cancer deaths in the United States. To tackle this issue, Damon Runyon Fellow Aaron L. Moye, PhD, and colleagues have developed a platform to study early-stage lung cancer and to identify potential new treatments.
Faster, cheaper diagnostic tests for COVID-19 could potentially help control the spread of disease and facilitate safe openings of schools and businesses. Former Damon Runyon Innovator Feng Zhang, PhD, and colleagues have developed a CRISPR-based diagnostic for COVID-19 that gives accurate results in less than an hour and, in principle, could be made inexpensively to allow for regular testing at home.
COVID-19 has mobilized scientists across the globe in an unprecedented effort to understand the SARS-CoV-2 virus and stop this disease. Some Damon Runyon scientists have temporarily pivoted their research to contribute to this critical goal by investigating how the virus enters human cells, developing more efficient testing, and searching for treatments.
Former Damon Runyon Fellow John Blenis, PhD, and colleagues at Weill Cornell Medicine have discovered a molecule produced by our own cells that can accumulate in the blood as we age and help cancer cells spread from one site in the body to others. The researchers found that the level of methylmalonic acid (MMA)—a by-product of protein and fat digestion—is significantly higher in the blood of otherwise healthy people over the age of 60.
Former Damon Runyon Clinical Investigator Andrew T. Chan, MD, MPH, and his colleagues at Massachusetts General Hospital in Boston and Monash University in Melbourne, Australia, have published surprising new results that for older individuals with advanced cancer, taking aspirin may increase their risk of cancer growth and early death.
Damon Runyon Fellow Lindsay M. LaFave, PhD, and colleagues at Massachusetts Institute of Technology and Harvard University, discovered that elevated levels of a protein called RUNX2 in human lung tumors predict a worse prognosis—a finding which could lead to new diagnostics and drug targets.
When cancer cells escape their primary tumor and move to the fluid and tissues surrounding the brain and spinal cord—a condition called leptomeningeal metastasis—the result is devastating. Now, Damon Runyon Clinical Investigator Adrienne A. Boire, MD, PhD, and colleagues at Memorial Sloan Kettering have discovered how these rogue cells are able to survive in the barren environment of the cerebral spinal fluid (CSF) and suggest a possible strategy for treatment.
A new publication from Damon Runyon Physician-Scientist Jonathan E. Shoag, MD, and colleagues at Weil Cornell Medicine shows that PSA screening has benefits beyond lowering prostate cancer death risk, such as prevention of metastatic disease and the impaired quality of life associated with its treatment. The researchers suggest that the balance of benefits and harms of screening may be more favorable than previously recognized.
CONNECT
1.877.7CANCER
info@damonrunyon.org
One Exchange Plaza
55 Broadway, Suite 302
New York, NY 10006
